Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
Autorzy:
Oh DY; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University Graduate School, Seoul, South Korea. . Maqueda MA; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Quinn DI; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA. O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA, USA. Chau I; The Royal Marsden NHS Foundation Trust-Royal Marsden Hospital, London, UK. Kim SY; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Duran I; Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain. Castellano D; Hospital Universitario, 12 de Octubre, Madrid, Spain. Berlin J; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. Mellado B; Medical Oncology Department, Hospital Clinic i Provincial de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. Williamson SK; University of Kansas Hospital Cancer Center, Kansas City, KS, USA. Lee KW; Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. Marti F; The Christie NHS Foundation Trust, Manchester, UK. Mathew P; Tufts Medical Center, Boston, MA, USA. Saif MW; Tufts Medical Center, Boston, MA, USA.; Orlando Health Cancer Institute, Orlando, FL, USA. Wang D; Henry Ford Hospital, Detroit, MI, USA. Chong E; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA. Hilger-Rolfe J; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA. DeanJP; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA. Arkenau HT; Sarah Cannon Research Institute - United Kingdom (SCRI-UK) and University College London, Cancer Institute, London, UK.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Nov 03; Vol. 23 (1), pp. 1056. Date of Electronic Publication: 2023 Nov 03.
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma.
Autorzy:
Mar N; Division of Hematology/Oncology, University of California Irvine, Orange, CA 92868, USA. Zakharia Y; Division of Hematology/Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA. Falcon A; Hospital Universitario Virgen del Rocío, 41013 Seville, Spain. Morales-Barrera R; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain. Mellado B; Medical Oncology Department, Hospital Clínic i Provincial de Barcelona, Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain. Duran I; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), 39011 Santander, Spain. Oh DY; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University Graduate School, Seoul 03080, Republic of Korea. Williamson SK; University of Kansas Hospital Cancer Center, Kansas City, KS 64114, USA. Gajate P; Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain. Arkenau HT; Sarah Cannon Research Institute United Kingdom (SCRI-UK) and University College London Cancer Institute, London W1G 6AD, UK. Jones RJ; Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow G12 0YN, UK. Teo MY; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Turan T; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA 94080, USA. McLaughlin RT; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA 94080, USA. Peltier HM; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA 94080, USA. Chong E; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA 94080, USA. Atluri H; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA 94080, USA. DeanJP; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA 94080, USA. Castellano D; Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2023 May 30; Vol. 15 (11). Date of Electronic Publication: 2023 May 30.
Outcomes of coronavirus disease 2019 (COVID-19) and risk factors associated with severe COVID-19 in patients with mature B-cell non-Hodgkin lymphomas: A US electronic health record cohort study.
Autorzy:
Yue X; AbbVie, Inc., North Chicago, Illinois, USA. Hallett D; AbbVie, Inc., North Chicago, Illinois, USA. Liu Y; AbbVie, Inc., North Chicago, Illinois, USA. Basa E; AbbVie, Inc., North Chicago, Illinois, USA. McNeill A; AbbVie, Inc., North Chicago, Illinois, USA. DeanJP; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California, USA.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2023 Feb; Vol. 110 (2), pp. 177-187. Date of Electronic Publication: 2022 Nov 15.
Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Autorzy:
Woyach J; Division of Hematology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USA. Tedeschi A; Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy. Munir T; Department of Haematology, St. James's University Hospital, Leeds, UK. Siddiqi T; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA. Hillmen P; Department of Haematology, The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, UK. Byrd JC; Division of Hematology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USA. Ghia P; Division of Experimental Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy. Mulligan SP; Department of Haematology, Royal North Shore Hospital, University of Sydney, Sydney, Australia. Dai S; Department of Biostatistics, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA. Amaya-Chanaga CI; Department of Medical Affairs, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA. DeanJP; Department of Clinical Science, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA. O'Brien SM; Department of Hematology and Oncology, UC Irvine, Chao Family Comprehensive Cancer Center, Irvine, CA, USA. Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2021 Dec; Vol. 62 (13), pp. 3278-3282. Date of Electronic Publication: 2021 Aug 13.
Comparing Antibody Responses in Chickens Against Plasmodium falciparum Lactate Dehydrogenase and Glyceraldehyde-3-phosphate Dehydrogenase with Freund's and Pheroid® Adjuvants.
Autorzy:
Krause RG; a Department of Biochemistry , University of KwaZulu-Natal , Scottsville , South Africa and. Grobler AF; b DST/NWU Preclinical Drug Development Platform, Faculty of Health Sciences, North-West University , Potchefstroom , South Africa. Goldring JP; a Department of Biochemistry , University of KwaZulu-Natal , Scottsville , South Africa and.
Evaluation of the Sexual Assessment Monitor, a diagnostic device used to electronically quantify ejaculatory latency time: findings from three studies.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
